It emphasizes the clinical outcomes of SGLT-2 inhibitors, like consistent reduction in HF hospitalization, while exploring GLP-1 receptor agonists that offer potential benefits in managing obesity-related HFpEF. The gene discussed is SLC5A2; the disease is obesity due to melanocortin 4 receptor deficiency.